ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
FOXC1-ATP7A Axis Activates PI3K/AKT Signaling to Suppress Cuproptosis and Drive Fibroblast Pathogenesis in Rheumatoid Arthritis.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation and progressive joint destruction. The underlying molecular mechanisms remain incompletely defined. Transcriptomic data of RA and normal synovial samples (GSE89408) were analyzed to identify the differentially expressed genes (DEGs). WGCNA, GO/KEGG enrichment, and PPI analysis were performed on the DEGs to screen for hub genes involved in RA progression. The proliferation, apoptosis, migration, and invasion of the MH7A fibroblast-like synoviocytes were evaluated through routine functional assays. QRT-PCR and Western blotting were conducted for molecular validation. Bioinformatics analyses identified FOXC1 as a hub transcription factor in RA and confirmed its co-expression with ATP7A. FOXC1 was markedly upregulated in RA tissues and fibroblasts, where it enhanced ATP7A expression. Overexpression of FOXC1 or ATP7A promoted the proliferation, invasion, and migration of RA fibroblasts while inhibiting apoptosis. Knockdown of ATP7A abrogated the effects of FOXC1. Mechanistically, the FOXC1-ATP7A axis activated PI3K/AKT/mTOR signaling and reduced markers of cuproptosis in the MH7A cells, suggesting an essential role in maintaining fibroblast pathogenicity. FOXC1 is a novel upstream regulator of ATP7A in synovial fibroblasts, and the FOXC1/ATP7A/PI3K/AKT pathway mediates RA pathogenesis by activating the synovial fibroblasts and suppressing cuproptosis. Targeting this axis may provide new therapeutic opportunities for RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.